Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

By M. Shah, K. Shitara, J. Ajani, Y. Bang, P. Enzinger, D. Ilson, F. Lordick, E. Van Cutsem, J. Gallego Plazas, Jing Huang and 11 more. 2023